Complete remission achieved with single agent CNTO 328, an anti-IL-6 monoclonal antibody, in relapsed and refractory myeloma

Clinical Lymphoma, Myeloma and Leukemia

Volumn 13, Issue 3, 2013, Pages 333-337

  Chari, Ajai ^a   Pri Chen, Hadass ^b   Jagannath, Sundar ^a  

^a MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^b HEBREW UNIVERSITY OF JERUSALEM   (Israel)

Author keywords

multiple myeloma

Indexed keywords

BENCE JONES PROTEIN; BORTEZOMIB; C REACTIVE PROTEIN; CALCIUM; CREATININE; CYCLOPHOSPHAMIDE; DEXAMETHASONE; DOXORUBICIN; HEMOGLOBIN; LENALIDOMIDE; MELPHALAN; PREDNISONE; SERUM ALBUMIN; SILTUXIMAB; THALIDOMIDE; VINCRISTINE;

ADULT; ANEMIA; ARTICLE; BONE MARROW; BONE MARROW BIOPSY; CANCER COMBINATION CHEMOTHERAPY; CANCER RECURRENCE; CANCER STAGING; CANCER STEM CELL; CASE REPORT; DYSPNEA; ERYTHEMA; ERYTHROCYTE SEDIMENTATION RATE; FEMALE; FLOW CYTOMETRY; HUMAN; HUMAN TISSUE; HYPOKALEMIA; INFECTIOUS COMPLICATION; JOINT STIFFNESS; LEUKOCYTE; LEUKOPENIA; MULTIPLE CYCLE TREATMENT; MUSCLE RIGIDITY; MYELOMA; NEUTROPENIA; NEUTROPHIL; NUCLEAR MAGNETIC RESONANCE IMAGING; PLASMA CELL; PROTEIN URINE LEVEL; RECURRENT CANCER; SIDE EFFECT; THROMBOCYTE; TREATMENT DURATION; WEIGHT GAIN;

ADULT; ANTIBODIES, MONOCLONAL; FEMALE; HUMANS; MULTIPLE MYELOMA; RECURRENCE; REMISSION INDUCTION;

EID: 84877772107     PISSN: 21522650     EISSN: 21522669     Source Type: Journal    
DOI: 10.1016/j.clml.2012.12.010     Document Type: Article

References (20)

1. E.B. Barton Interleukin-6 and new strategies for the treatment of cancer, hyperproliferative diseases and paraneolastic syndromes Expert Opin Ther Targets 9 2005 737 752
2. T.R. Ulich, J. del Castillo, K.Z. Guo In vivo hematologic effects of recombinant interleukin-6 on hematopoiesis and circulating numbers of RBCs and WBCs Blood 73 1989 108 110 (Pubitemid 19040962)
3. M.H. Zaki, J.A. Nemeth, M. Trikha CNTO 328, a monoclonal antibody to IL-6, inhibits human tumor-induced cachexia in nude mice Int J Cancer 111 2004 592 595 (Pubitemid 39045327)
4. K. Brocke-Heidrich, A.K. Kretzschmar, G. Pfeifer Interleukin-6-dependent gene expression profiles in multiple myeloma INA-6 cells reveal a Bcl-2 family-independent survival pathway closely associated with Stat3 activation Blood 103 2004 242 251 (Pubitemid 38029945)
5. D.M. Hilbert, M. Kopf, B.A. Mock Interleukin 6 is essential for in vivo development of B lineage neoplasms J Exp Med 182 1995 243 248
6. B.E. Barton, T.F. Murphy Constitutive expression of IL-6-LIKE cytokines in normal bone marrow: implications for pathophysiology of myeloma Cytokine 12 2000 1537 1545
7. H. Jernberg-Wiklund, M. Pettersson, M. Carlsson Increase in interleukin 6 (IL-6) and IL-6 receptor expression in a human multiple myeloma cell line, U-266, during long-term in vitro culture and the development of a possible autocrine IL-6 loop Leukemia 6 1992 310 318
8. J. Hardin, S. MacLeod, I. Grigorieva Interleukin-6 prevents dexamethasone-induced myeloma cell death Blood 84 1994 3063 3070 (Pubitemid 24328099)
9. F.H. Xu, S. Sharma, A. Gardner Interleukin-6-induced inhibition of multiple myeloma cell apoptosis: support for the hypothesis that protection is mediated via inhibition of the JNK/SAPK pathway Blood 92 1998 241 251 (Pubitemid 28303199)
10. P.M. Voorhees, Q. Chen, G.W. Small Targeted inhibition of interleukin-6 with CNTO 328 sensitizes pre-clinical models of multiple myeloma to dexamethasone-mediated cell death Br J Haematol 145 2009 481 490
11. P.M. Voorhees, Q. Chen, D.J. Kuhn Inhibition of interleukin-6 signaling with CNTO 328 enhances the activity of bortezomib in preclinical models of multiple myeloma Clin Cancer Res 13 2007 6469 6478 (Pubitemid 350075037)
12. R. Bataille, B. Barlogie, Z.Y. Lu Biologic effects of anti-interleukin-6 murine monoclonal antibody in advanced multiple myeloma Blood 86 1995 685 691
13. H.C. Van Zaanen, H.M. Lokhorst, L.A. Aarden Chimaeric anti-interleukin 6 monoclonal antibodies in the treatment of advanced multiple myeloma: a phase I dose-escalating study Br J Haematol 102 1998 783 790 (Pubitemid 28387063)
14. J.T. Beck, S.M. Hsu, J. Wijdenes Brief report: alleviation of systemic manifestations of Castleman's disease by monoclonal anti-interleukin-6 antibody N Engl J Med 330 1994 602 605 (Pubitemid 24065794)
15. F. Van Rhee, L. Fayad, P. Voorhees Siltuximab, a novel anti-interleukin-6 monoclonal antibody, for Castleman's disease J Clin Oncol 28 2010 3701 3708
16. M.J. Tisdale Mechanisms of cancer cachexia Physiol Rev 89 2009 381 410
17. D. Emilie, J. Wijdenes, C. Gisselbrecht Administration of an anti-interleukin-6 monoclonal antibody to patients with acquired immunodeficiency syndrome and lymphoma: effect on lymphoma growth and on B clinical symptoms Blood 84 1994 2472 2479 (Pubitemid 24317378)
18. R.N. Maini, P.C. Taylor, J. Szechinski Double-blind randomized controlled clinical trial of the interleukin-6 receptor antagonist, tocilizumab, in European patients with rheumatoid arthritis who had an incomplete response to methotrexate Arthritis Rheum 54 2006 2817 2829 (Pubitemid 44497760)
19. I. Nakamura, Y. Omata, M. Naito Blockade of interleukin 6 signaling induces marked neutropenia in patients with rheumatoid arthritis J Rheumatol 36 2009 459 460
20. B.A. Barut, L.I. Zon, M.K. Cochran Role of interleukin 6 in the growth of myeloma-derived cell lines Leuk Res 16 1992 951 959